Lantern Pharma - About the company
Lantern Pharma is a public company based in Dallas (United States), founded in 2013 by . It operates as a Developing drug and companion diagnostics for multi-drug resistant cancers. Lantern Pharma has raised $7.12M in funding from Green Park & Golf Ventures and Bios Partners. The company has 3227 active competitors, including 1093 funded and 745 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.
Company Details
Developing drug and companion diagnostics for multi-drug resistant cancers. Its approach is to biomarker-biased genetic screening to identify and treat patients that would benefit most from our drugs. Its lead candidate is Irovfulven-1, a new class of anti-tumor agents to treat multi-drug-resistant cancers.
- Website
- Social
- Email ID
- @lanternpharma.com
- Phone Number
- +1
Key Metrics
Founded Year
2013
Location
Dallas, United States
Stage
Public
Total Funding
in 5 rounds
Latest Funding Round
Investors
Ranked
156th among 3227 active competitors
Employee Count
as on Dec 31, 2022
Similar Companies
Exit Details
Public
Legal entities associated with Lantern Pharma
Lantern Pharma is associated with 3 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Feb 07, 2020 | - | 518 | 289 | |
Jan 14, 2020 | - | 766 | 280 | |
- | 711 | 166 |
Get your free copy of Lantern Pharma's company profile
Lantern Pharma's funding and investors
Lantern Pharma has raised a total funding of $7.12M over 5 rounds. Its first funding round was on Aug 28, 2014. Its latest funding round was a Grant (prize money) round on Jan 03, 2022 for $20K. 1 investor participated in its latest round, which include Bios Partners, Health Wildcatters and Green Park & Golf Ventures.
Lantern Pharma has 4 institutional investors including Green Park & Golf Ventures, Bios Partners and Health Wildcatters.
Here is the list of recent funding rounds of Lantern Pharma:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jan 03, 2022 | $20K | Grant (prize money) | 7867130 | 9687216 | |
Mar 18, 2019 | $2.39M | Series A | 1949538 | 4195527 | - |
May 02, 2017 | $3.7M | Series A | 3903326 | 2510565 |
Access funding benchmarks and valuations. Sign up today!View details of Lantern Pharma's funding rounds and investors
Lantern Pharma's founders and board of directors
The founders of Lantern Pharma is . is the CEO of Lantern Pharma. has founded 2 more companies - Covid 19 Monitoring and Intuition Systems.
View details of Lantern Pharma's Founder profiles and Board Members
Lantern Pharma's employee count trend
Lantern Pharma has 23 employees as of Dec 22. The total employee count is 43.8% more than what it was in Dec 21. Here is Lantern Pharma's employee count trend over the years:
Uncover Lantern Pharma's growth story! Sign up today!Lantern Pharma's Competitors and alternates
Top competitors of Lantern Pharma include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of Lantern Pharma, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of therapeutics for cancer and neurological disorders | $265M | InterWest Partners, Versant VenturesÌý&²¹³¾±è;Ìý | 86/100 |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Flagship Pioneering, WellingtonÌý&²¹³¾±è;Ìý | 85/100 |
3rd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, TemasekÌý&²¹³¾±è;Ìý | 84/100 |
4th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | HBM Partners, Seventure PartnersÌý&²¹³¾±è;Ìý | 83/100 |
5th | Recursion 2013, United States, Public | R&D based company focused on manufacturing of drugs for multiple therapeutic areas | $452M | HTIF, Menlo VenturesÌý&²¹³¾±è;Ìý | 81/100 |
6th | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | Sofinnova Investments, Foresite CapitalÌý&²¹³¾±è;Ìý | 79/100 |
7th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Tekla Capital Management, BB BiotechÌý&²¹³¾±è;Ìý | 78/100 |
8th | Illumina 1993, Public | Developer of technologies for analysis of genetic variation and function | $28M | Tekla Capital Management, VenrockÌý&²¹³¾±è;Ìý | 78/100 |
9th |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | 78/100 | |
10th | Blueprint Medicines 2008, Cambridge (United States), Public | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Foresite Capital, RocheÌý&²¹³¾±è;Ìý | 77/100 |
156th |  Lantern Pharma 2013, Dallas (United States), Public | Developing drug and companion diagnostics for multi-drug resistant cancers | $7.12M | Bios Partners, Health WildcattersÌý&²¹³¾±è;Ìý | 59/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Lantern Pharma's competitors? Click to see the top ones
Lantern Pharma's Investments and acquisitions
Lantern Pharma has made no investments or acquisitions yet.
Reports related to Lantern Pharma
Here is the latest report on Lantern Pharma's sector:
View
News related to Lantern Pharma
Media has covered Lantern Pharma for a total of 19 events in the last 1 year, 9 of them have been about company updates and 3 about partnerships.
•
Business Wire•Mar 28, 2025•Lantern Pharma
•
Business Wire•Feb 19, 2025•Lantern Pharma
•
Business Wire•Jan 27, 2025•Lantern Pharma
•
Clinical Trials Arena•Dec 09, 2024•Lantern Pharma
•
Business Wire•Dec 09, 2024•Lantern Pharma
•
Business Wire•Nov 26, 2024•Lantern Pharma
•
Business Wire•Nov 19, 2024•Lantern Pharma
•
Business Wire•Nov 08, 2024•Lantern Pharma
•
Business Wire•Oct 15, 2024•Lantern Pharma
•
Business Wire•Sep 23, 2024•Lantern Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Lantern Pharma
When was Lantern Pharma founded?
Lantern Pharma was founded in 2013.Where is Lantern Pharma located?
Lantern Pharma is located in Dallas, United States.When was the latest funding round of Lantern Pharma?
Lantern Pharma's latest funding round was on Jan 03, 2022.What is the annual revenue of Lantern Pharma?
Annual revenue of Lantern Pharma is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Fine Handling - 2008 founded, Unfunded company
- Pubcare - Fukuoka based, 2020 founded, Unfunded company
- Artesian Scrubbing Bubbles - Martinsville based, Unfunded company
- Three Point O Labs - Hyderabad based, 2022 founded, Unfunded company
- All Klaipeda Hotels - Klaipeda based, 2016 founded, Unfunded company
- Grandmas Jam House - 1995 founded, Unfunded company
